甲狀腺乳頭狀癌并BRAFV600E突變及原癌基因重排蛋白表達(dá)與其侵襲性的關(guān)系

孟 超，高 潔，梁 軍，梁智勇，林巖松

1青島大學(xué)醫(yī)學(xué)院附屬醫(yī)院腫瘤科，青島 266003中國(guó)醫(yī)學(xué)科學(xué)院 北京協(xié)和醫(yī)學(xué)院 北京協(xié)和醫(yī)院 2病理科 3核醫(yī)學(xué)科，北京 100730

·論著·

甲狀腺乳頭狀癌并BRAFV600E突變及原癌基因重排蛋白表達(dá)與其侵襲性的關(guān)系

孟 超1，高 潔2，梁 軍1，梁智勇2，林巖松3

1青島大學(xué)醫(yī)學(xué)院附屬醫(yī)院腫瘤科，青島 266003中國(guó)醫(yī)學(xué)科學(xué)院 北京協(xié)和醫(yī)學(xué)院 北京協(xié)和醫(yī)院2病理科3核醫(yī)學(xué)科，北京 100730

目的探討B(tài)RAFV600E突變及原癌基因重排 (RET) 蛋白表達(dá)并存與甲狀腺乳頭狀癌(PTC)侵襲性的關(guān)系。方法收集50例PTC患者術(shù)后病理，分別用RT-PCR檢測(cè) BRAFV600E突變，免疫組織化學(xué)SP法檢測(cè)RET表達(dá)情況。分析BRAFV600E突變合并RET表達(dá)組(n=24)和BRAFV600E單突變或RET單表達(dá)組 (n=19)的臨床及病理特征。結(jié)果BRAFV600E突變率、 RET表達(dá)率分別為76%(38/50)、56%(28/50)，存在BRAFV600E突變合并RET表達(dá)者占48%(24/50)。與BRAFV600E突變合并RET表達(dá)組比較， BRAFV600E單突變或RET單表達(dá)組腫瘤組織分化程度差，且甲狀腺癌評(píng)分系統(tǒng)評(píng)分較高(P=0.011，P=0.022)。結(jié)論BRAFV600E突變并存RET表達(dá)時(shí)提示PTC腫瘤組織分化差、更易出現(xiàn)實(shí)體亞型等侵襲性較高的病理亞型，有可能增加腫瘤相關(guān)死亡風(fēng)險(xiǎn)。

BRAFV600E突變；原癌基因重排蛋白表達(dá)；甲狀腺乳頭狀癌；侵襲性

ActaAcadMedSin,2013,35(1):64-68

甲狀腺乳頭狀癌(papillary thyroid cancer, PTC)是甲狀腺惡性腫瘤中最常見(jiàn)的一種類(lèi)型，發(fā)病率為70%～80%[1]。Xing等[2]對(duì)近30篇PTC相關(guān)基因突變文獻(xiàn)分析后總結(jié)其BRAFV600E突變率為29%～83%，即15外顯子第1799位核苷酸T被A取代，導(dǎo)致600密碼子編碼的纈氨酸被谷氨酸替代(V600E)[3-4]，與PTC的局部淋巴結(jié)及遠(yuǎn)處轉(zhuǎn)移相關(guān)[5-6]。原癌基因重排(rearranged during transfection proto-oncogene，RET)蛋白，尤其是RET/PTC活化表達(dá)不僅是PTC的致病因之一，還與其局部侵襲性[7]、預(yù)后及復(fù)發(fā)[8]有關(guān)。目前國(guó)內(nèi)外研究二者突變并存的文獻(xiàn)較少，Musholt等[9]對(duì)可疑PTC患者的細(xì)針穿刺活檢組織聯(lián)合行BRAFV600E突變及RET/PTC檢測(cè)，有助于PTC術(shù)前診斷、惡性程度評(píng)估及優(yōu)化手術(shù)方式。Henderson等[10]對(duì)PTC復(fù)發(fā)人群的研究結(jié)果提示二者雙突變可能與PTC復(fù)發(fā)有關(guān)。在臨床工作中PTC患者可同時(shí)出現(xiàn)BRAFV600E突變及RET表達(dá)，有關(guān)BRAFV600E突變和RET表達(dá)并存與其侵襲性的關(guān)系，目前報(bào)道較少。本研究擬對(duì)初診PTC患者手術(shù)切除腫瘤組織行BRAF、RET檢測(cè)，旨在分析BRAFV600E突變和RET表達(dá)并存與PTC侵襲性之間的關(guān)系。

資料和方法

標(biāo)本來(lái)源選取北京協(xié)和醫(yī)院2011年11月至2012年2月甲狀腺全切除術(shù)后病理確診為PTC并均無(wú)遠(yuǎn)處轉(zhuǎn)移的50例患者，男女比為1∶2.1，平均年齡(40.49±11.44)歲。所有患者術(shù)后病理組織學(xué)切片均由2位高年資病理醫(yī)師復(fù)查確認(rèn)為PTC，其中PTC亞型包括濾泡亞型9例、實(shí)體亞型10例、淋巴上皮瘤樣亞型及透明細(xì)胞型各1例(因亞型罕見(jiàn)未行分析)。

RT-PCR法檢測(cè)PTC組織中BRAFV600E突變

組織DNA提?。簢?yán)格按QIAamp DNA FFPE Tissue Kit(50)(中美艾德AmoyDX公司)說(shuō)明書(shū)進(jìn)行。紫外光光度計(jì)檢測(cè)DNA純度及濃度。

PCR擴(kuò)增：取cDNA 5 μl，上下游引物各35 μl，TaqDNA聚合酶0.4 μl等，加入PCR反應(yīng)體系中擴(kuò)增。反應(yīng)條件：95℃ 5 min 1個(gè)循環(huán)； 95℃ 25 s，64℃ 20 s，72℃ 20 s 15個(gè)循環(huán)； 93℃ 25 s，60℃ 35 s，72℃ 20 s 31個(gè)循環(huán)。

PCR產(chǎn)物分析：(1)確定實(shí)驗(yàn)是否成功可信：待測(cè)樣品的內(nèi)控內(nèi)對(duì)照信號(hào)(VIC信號(hào))應(yīng)升起。(2)確認(rèn)未選擇校正熒光參照，按管號(hào)順序依次選擇單一突變檢測(cè)反應(yīng)管進(jìn)行檢測(cè)分析。需要同時(shí)選擇陽(yáng)性質(zhì)控品反應(yīng)孔、無(wú)模板對(duì)照孔和樣品反應(yīng)孔，然后根據(jù)實(shí)際情況調(diào)節(jié)閾值至目的基因FAM擴(kuò)增曲線升起的拐點(diǎn)處，得到突變組的Ct值，即熒光達(dá)到閾值時(shí)候的PCR循環(huán)次數(shù)。若樣本的Ct大于或等于28，則樣本為陰性;若樣本的Ct小于28，則樣本為陽(yáng)性。

免疫組織化學(xué)法檢測(cè)RET在PTC組織中的表達(dá)標(biāo)本經(jīng)4%甲醛溶液固定，常規(guī)石蠟包埋，4μm厚連續(xù)切片，分別行HE和免疫組織化學(xué)染色。采用免疫組織化學(xué)SP法(免疫組織化學(xué)試劑購(gòu)于丹麥DAKO公司，RET鼠抗人單克隆抗體為即用型制劑)，具體操作步驟按試劑說(shuō)明書(shū)進(jìn)行，以1 mmol/L的EDTA pH 9.0 修復(fù)液進(jìn)行高壓鍋抗原修復(fù)，DBS溶液顯色，蘇木精復(fù)染，中性樹(shù)膠封閉，鏡下觀察。RET陽(yáng)性表達(dá)位于細(xì)胞漿，<5%細(xì)胞著色為陰性，≥5%細(xì)胞著色為陽(yáng)性。

結(jié) 果

PTC腫瘤組織BRAFV600E突變、RET表達(dá)情況76% (38/50)患者檢測(cè)到BRAFV600E突變；56% (28/50)患者癌組織中檢測(cè)出RET表達(dá)，2例患者癌旁正常組織中檢測(cè)出RET蛋白表達(dá)(合并橋本氏甲狀腺炎和結(jié)節(jié)性甲狀腺腫者各1例)；48% (24/50)患者同時(shí)存在BRAFV600E突變及RET表達(dá)，19例患者為BRAFV600E單突變或RET單表達(dá)，7例患者既不存在BRAFV600E突變也無(wú)RET表達(dá)(統(tǒng)計(jì)數(shù)據(jù)時(shí)已將其剔除)。

臨床病理特征BRAFV600E突變和RET表達(dá)并存組(G1組)患者腫瘤組織呈中分化者明顯高于二者單表達(dá)組(G2組)(P=0.011)；G1組患者實(shí)體亞型者明顯高于G2組(P=0.020)；甲狀腺乳頭狀癌評(píng)分系統(tǒng)(MACIS評(píng)分)高于G2組(P=0.022)。G1組中患者腫瘤侵出甲狀腺包膜與周?chē)M織黏連例數(shù)明顯高于G2組(P=0.036)(表1、圖1)。

表 1 兩組患者臨床病理資料比較

G1組：BRAFV600E突變合并RET表達(dá)組；G2組：BRAFV600E單突變或RET單表達(dá)組；RET:原癌基因重排；Nx：未被評(píng)估的局部結(jié)節(jié)

GroupG1: concurrent BRAFV600Eand RET protein expression; GroupG2: only one of BRAFV600Emutation and RET protein expression; RET: rearranged during transfection proto-oncogene; Nx：regional nodes cannot be assessed

G1組：BRAFV600E突變合并RET表達(dá)組；G2組：BRAFV600E單突變或RET單表達(dá)組GroupG1: concurrent BRAFV600E and RET protein expression; GroupG2: only one of BRAFV600E mutation and RET protein expression圖 1 兩組患者腫瘤組織實(shí)體亞型、中分化程度及包膜侵犯發(fā)生率Fig 1 Percentages of solid variant, moderately differentiation and extrathyroid invasion in two groups

討 論

PTC是甲狀腺惡性腫瘤中最常見(jiàn)的類(lèi)型[1]，經(jīng)甲狀腺全切或次全切除術(shù)輔以選擇性131I治療及甲狀腺激素抑制治療后，大多數(shù)患者預(yù)后較好，但仍約30%復(fù)發(fā)率[11]。包膜侵犯、頸部淋巴結(jié)轉(zhuǎn)移可使PTC腫瘤組織侵襲性增強(qiáng)，導(dǎo)致患者10年生存率下降[12]。研究顯示PTC患者BRAFV600E突變率為29%～83%[2]，RET/PTC重排發(fā)生率為17%～44%[13]。二者均與PTC患者局部侵襲性、預(yù)后及復(fù)發(fā)相關(guān)[5-8,14]。有關(guān)BRAFV600E突變合并RET表達(dá)對(duì)PTC侵襲性影響的報(bào)道較少，Musholt等[9]證實(shí)聯(lián)合檢測(cè)BRAFV600E突變及RET/PTC異常表達(dá)有助于PTC術(shù)前細(xì)針穿刺活檢組織診斷、惡性程度評(píng)估及優(yōu)化手術(shù)方式；針對(duì)復(fù)發(fā)性PTC的研究顯示BRAFV600E突變和RET/PTC重排并存可能與PTC復(fù)發(fā)及惡性程度有關(guān)[10]。本研究首次觀察了PTC患者初次手術(shù)病理BRAFV600E突變并存RET表達(dá)與PTC侵襲性的關(guān)系，結(jié)果顯示BRAFV600E突變和RET表達(dá)并存組(G1組)患者包膜外侵犯率明顯高于單一突變或表達(dá)組(G2組)，提示兩者并存時(shí)腫瘤組織的侵襲性更高。

PTC患者腫瘤組織的侵襲性與其分化程度及病理亞型類(lèi)型有關(guān)。RET原癌基因高表達(dá)，RAS/BRAF/MAPK信號(hào)通路持續(xù)激活被認(rèn)為是PTC發(fā)病的主要分子機(jī)制之一，影響PTC腫瘤組織的分化程度及亞型[15]。Kakudo等[16]研究提示中分化甲狀腺癌患者10年生存率較經(jīng)典型甲狀腺癌者下降約20%，提示其預(yù)后較差。實(shí)體亞型是PTC病理特殊組織學(xué)亞型，屬于侵襲性強(qiáng)、預(yù)后差的類(lèi)型，其患者頸部淋巴結(jié)及遠(yuǎn)處轉(zhuǎn)移率、復(fù)發(fā)率高[16-18]。本研究G1組PTC患者腫瘤組織呈中分化者明顯高于G2組，同時(shí)實(shí)體亞型者明顯高于G2組，提示BRAFV600E突變和RET表達(dá)并存時(shí)使PTC腫瘤組織分化程度降低、更易出現(xiàn)實(shí)體亞型等侵襲性較高的病理亞型。

MACIS評(píng)分主要依據(jù)患者年齡、原發(fā)腫瘤直徑、局部侵犯情況、是否完全切除及遠(yuǎn)處轉(zhuǎn)移進(jìn)行計(jì)算。有報(bào)道MACIS評(píng)分>6時(shí)可作為PTC患者死亡率的預(yù)測(cè)指標(biāo)之一，其分值高，提示PTC患者腫瘤組織的侵襲性增強(qiáng)，生存率降低[19]。本研究G1組PTC患者M(jìn)ACIS評(píng)分較G2組高，分析其原因主要與本組患者包膜侵犯率較高有關(guān)，提示BRAFV600E突變和RET表達(dá)并存時(shí)，患者腫瘤組織侵襲性增高，增加了腫瘤相關(guān)死亡風(fēng)險(xiǎn)。

將G2組進(jìn)一步分為兩個(gè)亞組，即BRAFV600E突變或RET單表達(dá)組，兩組患者病理資料差異無(wú)統(tǒng)計(jì)學(xué)意義，可能與患者病例數(shù)較少有關(guān)，在今后研究中將增加病例數(shù)繼續(xù)對(duì)其進(jìn)一步觀察。

綜上，PTC患者初次術(shù)后病理BRAFV600E突變和RET表達(dá)并存時(shí)與腫瘤組織的侵襲性明顯相關(guān)，使其具有更高包膜侵犯率，導(dǎo)致分化程度變差且更易出現(xiàn)實(shí)體亞型等侵襲性較高的病理亞型，有可能增加腫瘤相關(guān)死亡風(fēng)險(xiǎn)。

[1] Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy[J]. Endocrinol Metab Clin North Am, 1995, 24(4):711-760.

[2] Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2):245-262.

[3] Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage[J]. Nat Rev Mol Cell Biol, 2004, 5(11):875-885.

[4] Wojciechowska K, Lewinski A. BRAF mutations in papillary thyroid carcinoma[J]. Endocr Regul, 2006, 40(4):129-138.

[5] Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis [J].Cancer, 2012, 118(7):1764-1773.

[6] Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J]. Ann Surg, 2007, 246(3):466-470.

[7] Wang YL，Zhang RW，Luo ZW，et al. High frequency of level Ⅱ-Ⅴ lymph node involvement in RET/PTC positive papillary thyroid carcinoma[J]. Eur J Surg Oncol, 2008,34(1):77-781.

[8] Kogan EA, Rozhkova EB, Seredin VP, et al. Prognostic value of the expression of thyreoglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemical studies[J]. Arkh Patol, 2006, 68(4):8-11.

[9] Musholt TJ, Fottner C, Weber MM, et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules[J]. World J Surg, 2010, 34(11):2595-2603.

[10] Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutation associated with recurrent papillary thyroid carcinoma[J]. Clin Cancer Res, 2009, 15(2):485-491.

[11] Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm[J]. Endocrinol Metab Clin N Am, 2008, 37(2):419-435.

[12] Hamzany Y, Soudry E, Strenov Y. et al. Early death from papillary thyroid carcinoma[J]. Am J Otolaryngol, 2012, 33(1):104-108.

[13] Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity[J]. J Clin Endocrinol Metab, 2006, 91(9):3603-3610.

[14] Zafón C, Castellví J, Obiols G. Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis[J]. Endocrinol Nutr, 2010, 57(4):165-169.

[15] Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications[J]. J Chin Med Assoc,2010, 73(3):113-128.

[16] Kakudo K, Bai YH, Katayama S. et al. Classification of follicular cell tumors of the thyroid gland: analysis invoving Japanese patients form one institute[J]. Pathol Int, 2009, 59(6):359-367.

[17] Nikiforov YE, Erickson LA, Nikiforova MN,et al. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior[J]. Am J Surg Pathol, 2001, 25(12):1478-1484.

[18] Silver CE, Owen RP, Rodrigo JP, et al. Aggressive variants of papillary thyroid carcinoma[J]. Head Neck, 2011, 33(7):1052-1059.

[19] Holler T, Theriault J, Payne RJ, et al. Prognostic factors in patients with multiple recurrences of well-differentiated thyroid carcinoma[J]. J Oncol, 2009, doi:10.1155/2009/650340.

Invasive Properties of Papillary Thyroid Cancer with Concurrent BRAFV600EMutationand Rearranged during Transfection Proto-oncogene Protein Expression

MENG Chao1, GAO Jie2, LIANG Jun1, LIANG Zhi-yong2, LIN Yan-song3

1Department of Oncology, the Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, China2Department of Pathology,3Department of Nuclear Medicine, PUMC Hospital，CAMS and PUMC, Beijing 100730, China

LIN Yan-song，Tel：010-69155610,E-mail:linyansong68@yahoo.com.cn

Objective To investigate the aggressive properties of papillary thyroid cancer (PTC) with concurrent BRAFV600Emutation and rearranged during transfection (RET) proto-oncogene protein expression.MethodsFifty pathologically confirmed PTC patients who had

thyroidectomy were enrolled in this study. BRAFV600Emutation was detected by real time polymerase chain reaction (RT-PCR), while RET protein expression was measured by immunohistochemical SP method. Clinical and pathological features were compared between the concurrent BRAFV600Emutation and RET protein expression group (n=24) and BRAFV600Emutation or RET protein expression alone group (n=19). Seven patients were ruled out from the final analysis due to the absence of either BRAFV600Emutation or RET protein expression.ResultsOf these 50 patients, BRAFV600Emutation and RET protein expression were detected in 38 patients (76%) and 28 patients (56%), respectively. Concurrent BRAFV600Emutation and RET expression was detected in 24 patients (48%). Compared with the concurrent BRAFV600Emutation and RET protein expression group, the BRAFV600Emutation or RET protein expression alone group had relatively poorer tissue differentiation and higher prognostic score (P=0.011，P=0.022).ConclusionPTC patients with concurrent BRAFV600Emutation and RET expression present poorer differentiation, more highly aggressive variant in carcinoma tissues, and higher cancer-related mortality risk.

BRAFV600Emutation; tyrosine kinase receptor protein expression; papillary thyroid cancer; aggressiveness

國(guó)家自然科學(xué)基金(30970850)和衛(wèi)生行業(yè)科研專(zhuān)項(xiàng)項(xiàng)目(201202012)Supported by the National Natural Sciences Foundation of China (30970850)and the Research Special Fund of the Health Industry(201202012)；第一、二位作者對(duì)本文貢獻(xiàn)一致The first two authors contributed equally to this article

林巖松 電話：010-69155610，電子郵件：linyansong68@yahoo.com.cn

R736.1

A

1000-503X(2013)01-0064-05

10.3881/j.issn.1000-503X.2013.01.012

2012-04-25)